Article
Food Science & Technology
Valentina Cecarini, Massimiliano Cuccioloni, Yadong Zheng, Laura Bonfili, Chunmei Gong, Mauro Angeletti, Pedro Mena, Daniele Del Rio, Anna Maria Eleuteri
Summary: The study investigates how phenyl-gamma-valerolactone metabolites modulate cellular proteolysis by inhibiting proteasomes, upregulating autophagy, and inhibiting cathepsin B activity, resulting in reduced amyloid-beta (1-42) peptides. The findings suggest that these metabolites have neuroprotective effects by regulating intracellular proteolysis and could be potential targets for AD preventive and therapeutic strategies.
MOLECULAR NUTRITION & FOOD RESEARCH
(2021)
Article
Medicine, Research & Experimental
Eunbi Cho, Kumju Youn, Huiyoung Kwon, Jieun Jeon, Wan-Seob Cho, Se Jin Park, Seung Hwan Son, Dae Sik Jang, Chan Young Shin, Minho Moon, Mira Jun, Nam-Jung Kim, Dong Hyun Kim
Summary: This study investigated the effects of eugenitol in an AD mouse model and found that it inhibits the formation of A beta plaques and reduces neuronal cell death. In silico docking simulation showed that eugenitol may interact with A beta monomers and fibrils.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Clinical Neurology
Sarah F. Ackley, Jingxuan Wang, Ruijia Chen, Melinda C. Power, Isabel Elaine Allen, M. Maria Glymour
Summary: A Bayesian approach was used to analyze the results of several trials on amyloid-targeting drugs, indicating a small benefit of amyloid reduction on cognition.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Fardin Nabizadeh, Parya Valizadeh, Mohammad Balabandian
Summary: This study found that the use of statin drugs may help slow down or stabilize Aβ deposition in subjects without cognitive impairment. However, once clinical symptoms of cognitive impairment appear, statins fail to slow down Aβ deposition. Overall, statin users may have slower Aβ aggregation compared to non-users.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Economics
Hu Wang, Hong Shen, Shouwei Li
Summary: This study examines the impact of green bond issuance on the carbon risk of Chinese listed firms from 2009 to 2019. The findings suggest that green bond issuance reduces firms' carbon risk, with energy efficiency and energy consumption structure serving as channels for this effect. Furthermore, the study demonstrates that the negative impact of green bond issuance on carbon risk is more significant for firms with lower issuance costs and a higher level of digital transformation.
ECONOMIC MODELLING
(2023)
Article
Biochemistry & Molecular Biology
Shin-Meng Deng, Chia-Jung Chen, Hung-Lung Lin, Irene H. Cheng
Summary: Alzheimer's disease is a neurodegenerative disease with no effective prevention or treatment, but dietary modulation of the gut-brain axis can potentially delay the progression of AD by reducing neuroinflammation and alleviating cognitive deficits.
Article
Cell Biology
De-Juan Yuan, Guang Yang, Wei Wu, Qi-Fa Li, De-en Xu, Michael Ntim, Chun-Yan Jiang, Ji-Chuan Liu, Yue Zhang, Ying-Zi Wang, Dan-Dan Zhu, Supratik Kundu, Ai-Ping Li, Zhi-Cheng Xiao, Quan-Hong Ma, Shao Li
Summary: The reduction of VGSC alpha-subunit Nav1.6 in the hippocampus of APP/PS1 transgenic mice can improve cognitive impairments, attenuate synaptic deficits, reduce amyloid plaques, and lower levels of soluble A beta. Interfering with Nav1.6 suppresses BACE1 transcription, reduces intracellular calcium overload, and alleviates synaptic loss, ultimately improving learning and memory disorders in APP/PS1 mice. This study offers a potential therapeutic strategy for countering hippocampal hyperexcitability and rescuing cognitive deficits in AD by selectively targeting Nav1.6 overexpression and hyperactivity.
Article
Neurosciences
Caden M. Henningfield, Miguel A. Arreola, Neelakshi Soni, Elizabeth E. Spangenberg, Kim N. Green
Summary: Previous studies indicate that microglial-expressed ApoE may not be necessary for plaque formation in Alzheimer's disease. However, it may play a role in plaque homeostasis in disease and synaptic maintenance under normal conditions.
Review
Biochemistry & Molecular Biology
JiMin Kim, Hanna Jeon, Hye Yun Kim, YoungSoo Kim
Summary: Alzheimer's disease is a common cause of dementia, and an effective therapy is urgently needed. The amyloid hypothesis suggests that abnormal production and ineffective removal of amyloid-beta is the cause of AD. While a lot of focus is on immunotherapy, chemical drugs also have potential in clearing pathogenic proteins. This review evaluates and summarizes the prospect of chemical drugs targeting amyloid-beta based on candidates from the AlzForum database.
Review
Geriatrics & Gerontology
Guy C. Brown, Peter St George-Hyslop
Summary: TREM2 is a pattern recognition receptor expressed on myeloid cells that plays a crucial role in Alzheimer's disease. Soluble TREM2 (sTREM2) has a protective effect by blocking Aβ fibrillization and neurotoxicity. Higher levels of sTREM2 are associated with slower progression of AD.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Biochemistry & Molecular Biology
David Vicente-Zurdo, Noelia Rosales-Conrado, M. Eugenia Leon-Gonzalez, Leonardo Brunetti, Luca Piemontese, A. Raquel Pereira-Santos, Sandra M. Cardoso, Yolanda Madrid, Silvia Chaves, M. Amelia Santos
Summary: Alzheimer's disease (AD) is a serious and prevalent neurodegenerative disorder for which there is no cure. Recent research has focused on developing multi-target compounds for anti-AD drugs. In this study, seven novel RIV-BIM hybrids were developed and studied. These hybrids combine the active part of the drug rivastigmine with isomeric hydroxyphenylbenzimidazole units. The hybrids showed inhibition of cholinesterases, inhibition of amyloid beta-peptide aggregation, antioxidation, and metal chelation. They also demonstrated good capacity to promote cell viability and neuroprotection. Therefore, the RIV-BIM hybrids have the potential to be drug candidates for AD with multi-target abilities.
Article
Cell Biology
Qi Shen, Xiaolei Wu, Zhan Zhang, Di Zhang, Sihua Yang, Da Xing
Summary: The study found that inducing gamma oscillations with non-invasive light flicker can reduce Alzheimer's disease-related pathology. By increasing the anchoring of amyloid precursor protein (APP) to the plasma membrane for non-amyloidogenic processing and interacting with KCC2, it helps maintain surface GABA(A) receptor alpha 1 levels and reduce beta-amyloid (A beta) production. These findings highlight the importance of enhancing APP trafficking to the plasma membrane in the reduction of A beta load in Alzheimer's disease.
Article
Polymer Science
Bing Han, Dezhen Peng, Jianjian Wang, Zu-Neng Lu
Summary: Two new coordination polymers based on Co(II) ions were synthesized for the treatment of Alzheimer's disease. The compounds were evaluated through experiments on animal models, measuring brain volume and weight, determining Aβ content, assessing inflammatory cytokines, and detecting ROS accumulation.
JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS
(2021)
Article
Clinical Neurology
Tobey J. Betthauser, Murat Bilgel, Rebecca L. Koscik, Bruno M. Jedynak, Yang An, Kristina A. Kellett, Abhay Moghekar, Erin M. Jonaitis, Charles K. Stone, Corinne D. Engelman, Sanjay Asthana, Bradley T. Christian, Dean F. Wong, Marilyn Albert, Susan M. Resnick, Sterling C. Johnson
Summary: Alzheimer's disease biomarkers are crucial for understanding disease progression and predicting symptoms. This study develops and evaluates methods for modeling amyloid accumulation and investigates factors influencing the timing of amyloid onset and impairment onset. The findings suggest that APOE genotype, rather than sex, is associated with amyloid onset age, and that higher APOEe4 dosage, being female, and older amyloid onset age shorten the time from amyloid onset to dementia.
Article
Nanoscience & Nanotechnology
Xian Guo, Qiaoshan Lie, Yanan Liu, Zhi Jia, Youcong Gong, Xiaoyu Yuan, Jie Liu
Summary: SeQDs, as a novel drug with multi-target therapeutic effects, show significant advantages in the treatment of Alzheimer's disease, including rapid penetration of the blood-brain barrier, inhibition of Aβ aggregation, reduction of tau protein phosphorylation, and reduction of oxidative stress, ultimately improving cognitive and memory abilities in AD patients.
ACS APPLIED MATERIALS & INTERFACES
(2021)
